Feel the Love

Confidential advice by phone or IM

“Some of the Celebrex’s detractors contend that its risks are still not fully understood, and argue that Pfizer is dragging its feet on a study — now nearly six years old — evaluating the drug’s heart risks. The study is scheduled to end in May 2014, the same month that Celebrex loses its patent protection and sales of the drug are expected to plunge.”

In Documents on Pain Drug Celebrex, Signs of Doubt and Deception - NYTimes.com

How convenient.

 Subscribe in a reader